Please login to the form below

Not currently logged in
Email:
Password:

ImmuNext

This page shows the latest ImmuNext news and features for those working in and with pharma, biotech and healthcare.

Lilly cuts deal with UK’s Sitryx for autoimmune disease drugs

Lilly cuts deal with UK’s Sitryx for autoimmune disease drugs

Last year, Lilly announced a $650m partnership with US biotech ImmuNext in the autoimmune disease area, which came just a few months after it launched a $620m partnership with Aduro Biotech

Latest news

  • Lilly and ImmuNext deal focused on autoimmune diseases Lilly and ImmuNext deal focused on autoimmune diseases

    In return, ImmuNext will grant Lilly a worldwide licence to develop and commercialise the novel immunometabolism target. ... In addition, Lilly and ImmuNext will establish a three year research collaboration to support the target's development.

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2017 Deal Watch January 2017

    625. Momenta. CSL. Licence. M230 immuno-modulator of Fc receptors. 600. ImmuNext.

  • Deal Watch December 2016 Deal Watch December 2016

    453. ImmuNext (US). Roche (Switzerland). Licence. Rights to develop and commercialise therapeutic products that agonise the VISTA (negative checkpoint regulator) signalling pathway. ... ImmuNext. Roche. $400m. Not disclosed. Products that agonise the

  • Pharma deals during September 2012 Pharma deals during September 2012

    Lebanese company Immunext is developing novel therapeutics that modulate the immune system to treat cancer, and has announced a deal with Janssen Biotech. ... Nanocyclix technology platform for kinase inhibitors. 168. ImmuNext / Janssen Biotech. Licence

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

DATA shutterstock_1818502577-640.jpg
Empowering patients empowers results
Patient-centricity is key when it comes to creating a more flexible, efficient and modern process for clinical trials...
Don’t limit diversity to just representation in clinical trials
What is the power of diversity in the healthcare environment? Can it make clinical trials more inclusive?...
Oh no… not more training
Paul Hutchings, founder of fox&cat, discusses ways to help your team manage pressure in a more human, pressure-centric and engaging way...

Infographics